ConcertAI, an artificial intelligence and data specialist, is teaming up with Louisiana State University (LSU) Health New Orleans for a five-year partnership to address diversity in clinical trials in the Gulf South region.
LSU Health, which is a National Cancer Institute (NCI) Community Oncology Research Program designee, will use ConcertAI’s ERACE (Engaging Research to Achieve Cancer Care Equality) program that uses AI and real-world data in clinical trials to overcome challenges such as time, money, boosting diversity, retention and recruitment.
These problems are particularly acute for the cancer research sector, which has a lot of money and high expectations riding on trials for the disease.
“LSU Health New Orleans and ConcertAI believe addressing disparities starts with a foundation of data and a diversity of clinical settings that explicitly assure the broadest representativeness and generalizability,” ConcertAI CEO Jeff Elton said in a release. “This, combined with the latest real-world analytic and AI-enabled software, assure insights progress to practice in weeks and months versus years.”
The partnership will assess results of a NCI program focused on underserved minority populations in the region. Also joining in the review is LSU Health’s Louisiana Tumor Registry, which is one of 21 cancer registries comprising the NCI’s Surveillance, Epidemiology, and End Results program.